tafinlar podcasts

FDA D.I.S.C.O. Burst Edition: FDA approval of Tafinlar (dabrafenib) with Mekinist (trametinib) for pediatric patients with low-grade glioma with a BRAF V600E mutation

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Play Episode Listen Later Apr 6, 2023 4:00

Listen to a soundcast of the March 16, 2023, FDA approval of Tafinlar (dabrafenib) for pediatric patients with low-grade glioma with a BRAF V600E mutation

fda grade disc mutation burst fda approval pediatric patients glioma braf v600e trametinib dabrafenib mekinist tafinlar

FDA D.I.S.C.O. Burst Edition: FDA approval of Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for unresectable or metastatic solid tumors with BRAF V600E mutation

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Play Episode Listen Later Jul 25, 2022 4:59

Listen to a soundcast of the June 22nd 2022 FDA approval of Tafinlar (dabrafenib) for in combination w/trametinib (brand name Mekinist) for unresectable or metastatic solid tumors with BRAF V600E mutation.

fda disc mutation burst combination fda approval metastatic solid tumors unresectable braf v600e trametinib dabrafenib mekinist tafinlar

CHMP Opinion in the Area of Oncology - Hodgkin Lymphoma

Health Professional Radio - Podcast 454422

Play Episode Listen Later Feb 28, 2021 9:14

Dr. Vicki Goodman, VP, Therapeutic Area Head, Late Stage Oncology at Merck discusses the recent Phase 3 KEYNOTE-204 positive EU CHMP opinion for expanded approval of KEYTRUDA® (pembrolizumab) for the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL) that meet certain criteria. Vicki Goodman, MD, is Vice President, Therapeutic Area Head for Late Stage Oncology at Merck. In this role, she oversees Merck’s portfolio in lung cancers, women’s cancers, hematology, and head and neck cancer. Vicki joined Merck from Bristol-Myers Squibb where most recently she was VP, Head, Clinical Development Center of Excellence. She is a hematologist and medical oncologist with 15 years of drug development experience in both government and industry. Vicki trained in internal medicine and hematology/oncology at the University of Michigan. She then served as a medical officer at FDA for over two years and subsequently worked at GlaxoSmithKline for eight years. While at GSK, Vicki took on roles of increasing responsibility and worked on a range of projects including pazopanib (Votrient) and dabrafenib (Tafinlar), alone and in combination with trametinib (Mekinist). She also led the development of several early to mid-stage oncology drug candidates. She joined BMS in January 2015 as Vice President, Development Leader for Opdivo/Yervoy in Melanoma and GU tumors. In this role, she oversaw the approval of the first I-O combination (Opdivo and Yervoy) in advanced melanoma, approval of Opdivo in adjuvant melanoma, RCC and bladder cancer, and the initiation of several key phase 3 programs. In July 2017, she was appointed to lead BMS new asset development teams, overseeing a portfolio of experimental assets between proof of concept and first regulatory approval. Vicki served as a senior advisor to the BMS women’s network, has lectured and served as a panelist in women’s oncology leadership forums including at the University of Pennsylvania Perelman School of Medicine. Vicki was profiled in Fierce Women in Biopharma in 2016 and recognized for her contributions to oncology development by Gilda’s Club NYC in 2017.

BRAF: A New Target to Treat in Lung Cancer

GRACEcast

Play Episode Listen Later Jul 16, 2015 4:19

A study released at ASCO 2015 showed that the BRAF V600E mutation had a high response rate to combination therapy Tafinlar (dabrafenib) plus Mekinist (trametinib), which led the doctors to agree that BRAF testing in lung cancer should become commonplace.

west therapy cancer institute treat swedish gandhi institut targeted therapies lung cancer soria asco jean charles gustave new target braf dana farber braf v600e gracecast cancergrace roussy trametinib dabrafenib mekinist tafinlar

BRAF: A New Target to Treat in Lung Cancer

GRACEcast Lung Cancer Video

Play Episode Listen Later Jul 16, 2015 4:19

A study released at ASCO 2015 showed that the BRAF V600E mutation had a high response rate to combination therapy Tafinlar (dabrafenib) plus Mekinist (trametinib), which led the doctors to agree that BRAF testing in lung cancer should become commonplace.

west therapy cancer institute treat swedish gandhi institut targeted therapies lung cancer soria asco jean charles gustave new target braf dana farber braf v600e gracecast cancergrace roussy trametinib dabrafenib mekinist tafinlar

BRAF: A New Target to Treat in Lung Cancer

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jul 16, 2015 4:19

A study released at ASCO 2015 showed that the BRAF V600E mutation had a high response rate to combination therapy Tafinlar (dabrafenib) plus Mekinist (trametinib), which led the doctors to agree that BRAF testing in lung cancer should become commonplace.